Pliant Therapeutics, Inc.

NASDAQ:PLRX

Biotechnology

Healthcare
$0.81 -3.39%

-$0.04 today

Market cap
$50.14M
Beta
1.21
P/E (TTM)
-0.6
EPS (TTM)
-$1.83
52W Low $1.09High $1.95

Volume 0.15M

Average 0.49M

PLRX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Pliant Therapeutics, Inc.NASDAQ: PLRX

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables dips below year-ago levels

Q1 FY2026 accounts payables of $118K (cash outflow) fell 65.1% year over year, behind the +350.7% change in trailing-twelve-month accounts payables. Sequentially, it rose 3833.3% from the prior quarter. Over 3 fiscal years it compounded at +59.5% a year.

Context

  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -65.1% toward the trailing-twelve-month pace of +350.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$118K+3833.3% QoQ
Last fiscal yearDec 2025
-$5.48M-483.8% YoY
LTMMar 2026
-$5.26M+350.7% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-65.1%——
1 year-483.8%——
3-year CAGR+59.5%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(5.48M) USD
Year-over-year change
-483.8%

Accounts Payables vs competitors

How PLRX compares with its peers on the latest reported figures

  • PLRX's LTM Mar 2026 accounts payables of $5.26M is the 2nd largest of the 10 companies compared; the peer median is $104K.
  • Its year-over-year change of +350.7% is the 2nd highest of 9, against a peer median of -51.7%.
  • Over three fiscal years its annual growth of +59.5% compares with a peer median of -38.0%.
PLRX Competitors Peer median
Accounts Payables for PLRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$12.77M +201.6%——
PLRXPliant Therapeutics, Inc.LTM Mar 2026$5.26M +350.7%+59.5%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$3.63M +320.5%-38.0%51.0%
STROSutro Biopharma, Inc.LTM Mar 2026$3.13M -534.1%+26.3%3.1%
MGNXMacroGenics, Inc.LTM Mar 2026$2.31M -48.2%-70.5%1.5%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$1.01M +447.4%——
COYACoya Therapeutics, Inc.LTM Mar 2026$783.6K -867.8%—9.9%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$170K -60.6%——
CLNNClene Inc.LTM Mar 2026$104K -55.2%—77.6%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$0 ——0.0%
Peer median (excluding PLRX) $104K-51.7%-38.0%6.5%

Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Depreciation & Amortization1.54M1.82M1.84M2.13M1.7M
Deferred Income Tax00000
Stock-Based Compensation10.44M22.6M44.48M37.63M26.23M
Change in Working Capital6.92M4.22M1.25M9.09M(15.94M)
Accounts Receivables7.28M15K1.98M00
Inventory00000
Accounts Payables891K(1.35M)2.97M1.43M(5.48M)
Other Working Capital(1.26M)5.55M(3.7M)7.66M(10.46M)
Other Non-Cash Items2.93M52K(2.6M)5.96M9.02M
Operating Cash Flow(75.44M)(94.63M)(116.36M)(155.5M)(128.34M)
Capital Expenditures(1.95M)(1.76M)(921K)(3.85M)(374K)
Acquisitions (Net)(75.65M)148.44M00155K
Purchases of Investments(219.89M)(325.72M)(583.07M)(211.29M)(203.4M)
Sales of Investments295.54M177.27M456.98M355.47M337.91M
Other Investing Activities75.65M(148.44M)000
Investing Cash Flow73.7M(150.2M)(127.01M)140.34M134.29M
Debt Repayment010M019.91M(32.27M)
Common Stock Issued2.98M215.64M275.25M3.21M570K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(457K)1.21M5M00
Financing Cash Flow2.53M226.85M274.41M23.12M(31.7M)
Effect of Forex Changes00000
Net Change in Cash783K(17.98M)31.03M7.95M(25.74M)
Free Cash Flow(77.4M)(96.39M)(117.28M)(159.35M)(128.71M)

Pliant Therapeutics, Inc.

NASDAQ:PLRX

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.